Article Figures & Data
Figures
- FIGURE 1.
Anterior (A) and posterior (P) views of a non-Hodgkin lymphoma patient imaged using 111In-ibritumomab tiuxetan at 4 h, day 3, and day 6 after infusion, showing decrease in normal organ activity over time with increase in lymph node prominence. (Courtesy of the University of Alabama at Birmingham.)
- FIGURE 2.
Biodistribution of 111In-ibritumomab in whole body and major organs with time after infusion. These decay-corrected (biologic) data plotted semilogarithmically represent mean values for 10 patients in this study (Table 5) to which single-exponential retention functions were applied.
Tables
- TABLE 1
Radiation Absorbed Doses per Unit Administered Activity from Intravenous Administration of 111In-Ibritumomab Tiuxetan
Target organ mGy/MBq Adrenals 0.202 ± 0.041 Brain 0.082 ± 0.020 Breasts 0.080 ± 0.016 Gallbladder wall 0.229 ± 0.059 Lower large intestine 0.130 ± 0.027 Small intestine 0.145 ± 0.027 Stomach wall 0.139 ± 0.028 Upper large intestine wall 0.147 ± 0.027 Heart wall 0.195 ± 0.048 Kidneys 0.315 ± 0.071 Liver 0.467 ± 0.202 Lungs 0.152 ± 0.036 Muscle 0.103 ± 0.021 Ovaries 0.138 ± 0.028 Pancreas 0.199 ± 0.041 Red marrow 0.272 ± 0.065 Osteogenic cells* 0.312 ± 0.050 Skin 0.065 ± 0.015 Spleen 0.464 ± 0.193 Testes 0.175 ± 0.076 Thymus 0.114 ± 0.024 Thyroid 0.098 ± 0.024 Urinary bladder wall 0.113 ± 0.028 Uterus 0.132 ± 0.029 Total body 0.124 ± 0.022 ↵* Bone surfaces.
Data are mean ± SD. Three significant figures do not imply precision of 1 in 1,000.
- TABLE 2
Radiation Absorbed Doses per Unit Administered Activity from Intravenous Administration of 90Y-Ibritumomab Tiuxetan
Target organ mGy/MBq Adrenals 0.379 ± 0.118 Brain 0.379 ± 0.118 Breasts 0.379 ± 0.118 Gallbladder wall 0.379 ± 0.118 Lower large intestine 0.379 ± 0.118 Small intestine 0.379 ± 0.118 Stomach wall 0.379 ± 0.118 Upper large intestine wall 0.379 ± 0.118 Heart wall 1.08 ± 0.394 Kidneys 2.44 ± 0.610 Liver 3.64 ± 1.389 Lungs 0.761 ± 0.488 Muscle 0.379 ± 0.118 Ovaries 0.379 ± 0.118 Pancreas 0.379 ± 0.118 Red marrow 2.73 ± 0.909 Osteogenic cells* 2.14 ± 0.519 Skin 0.379 ± 0.118 Spleen 4.65 ± 2.327 Testes 2.16 ± 0.842 Thymus 0.379 ± 0.118 Thyroid 0.379 ± 0.118 Urinary bladder wall 0.379 ± 0.118 Uterus 0.379 ± 0.118 Total Body 0.587 ± 0.107 ↵* Bone surfaces.
Data are mean ± SD. Three significant figures do not imply precision of 1 in 1,000.
Equilibrium dose constant, Δi Principal radiation Ei (keV)* ni (rad g μCi−1 h−1) (Gy kg Bq−1 s−1) Auger electron 2.7 0.98 5.68E−03 4.27E−16 19.3 0.156 6.41E−03 4.82E−16 Conversion electron 144.6 0.078 2.40E−02 1.80E−15 167.3 0.0106 3.78E−03 2.84E−16 170.5 0.00203 7.37E−04 5.54E−17 171.2 0.000424 1.55E−04 1.16E−17 218.7 0.0493 2.30E−02 1.73E−15 241.4 0.00785 4.04E−03 3.03E−16 244.6 0.00151 7.87E−04 5.91E−17 245.3 0.000301 1.57E−04 1.18E−17 x-ray 3.1 0.069 4.60E−04 3.46E−17 23 0.235 1.15E−02 8.64E−16 23.2 0.443 2.19E−02 1.64E−15 26.1 0.145 8.06E−03 6.06E−16 γ 171.3 0.902 3.29E−01 2.47E−14 245.4 0.94 4.91E−01 3.69E−14 ↵* Average electron energies.
Ei = mean energy per particle or photon; ni = mean number of particles or photons per nuclear transition; Δi = mean energy emitted per nuclear transition.
111In has the following properties: physical half-life, 67.3 h; decay constant, 0.0103 h−1; and decay mode, electron capture.
Equilibrium dose constant, Δi Principal radiation Ei (keV)* ni (rad g μCi−1 h−1) (Gy kg Bq−1 s−1) β 185.6 0.000115 4.55E−05 3.42E−18 933.7 0.9999 1.99E+00 1.49E−13 Auger electron 2.02 0.000118 5.08E−07 3.81E−20 Conversion electron 1,743 0.000102 3.79E−04 2.84E−17 ↵* Average β-energy.
90Y has the following properties: physical half-life, 64.1 h; decay constant, 0.0108 h−1; and decay mode, β(−).
Site Fraction initial uptake (±SD) Retention half-time (h ± SD) Residence time (h ± SD) Heart contents 0.0640 ± 0.0212 48.1 ± 15.8 1.18 ± 0.557 Kidneys 0.0262 ± 0.00780 106 ± 45.7 1.40 ± 0.351 Liver 0.145 ± 0.0253 141 ± 76.0 12.9 ± 4.92 Lungs 0.0394 ± 0.0126 46.6 ± 11.7 1.41 ± 0.904 Red marrow 0.146 ± 0.0283 286 ± 347 11.7 ± 4.52 Spleen 0.0417 ± 0.0143 106 ± 56.5 1.63 ± 0.814 Testes 0.00192 ± 0.00133 67.4 ± 6.86 0.163 ± 0.0650 Whole body 1.0 380 ± 162 Remainder of whole body 0.535 ± 0.0995 >400 (long) 51.8 ± 16.2 - TABLE 6
Comparison of Median Absorbed Doses per Unit Administered Activity from 90Y-Ibritumomab Tiuxetan for Selected Organs and Tissues
90Y-ibritumomab tiuxetan absorbed dose (mGy/MBq) in… Site This study Ibritumomab tiuxetan package insert (online and printed versions (6)) Cremonesi et al. (7) (method A) Heart wall 1.0 (0.6–2.0) 2.9 (1.5–3.2) 2.1 (1.1–5.4) Lungs 0.60 (0.31–1.6) 2.0 (1.2–3.4) 1.7 (0.3–3.5) Liver 3.1 (2.3–6.6) 4.8 (2.9–8.1) 2.8 (1.8–10.6) Kidneys 2.4 (1.4–3.9) 0.1 (0.0–0.3) 1.7 (0.6–3.8) Lower large intestinal wall 0.36* (0.24–0.62) 4.7 (3.1–8.2) Not reported Spleen 4.3 (0.98–9.0) 9.4 (1.8–20.0) 1.9 (0.8–5.0) Red marrow 2.4 (1.7–4.5) 1.3 (0.6–1.8) 0.8 (0.4–1.0) Testes 1.8 (1.5–3.8) 1.5 (1.0–4.3) 2.8 (1.3–4.7) Whole body 0.55 (0.44–0.81) 0.5 (0.4–0.7) 0.5 (0.4–0.8) ↵* Included as 1 of “other organs” or remainder tissues.
Range is presented in parentheses.
Jump to section
Related Articles
Cited By...
- A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806
- Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies
- Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
- Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
- A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
- A Small-Scale Anatomic Model for Testicular Radiation Dosimetry for Radionuclides Localized in the Human Testes
- Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab
- Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma
- Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial